Apellis Pharmaceuticals

• 

  10/3/2024

  **Iovance Biotherapeutics Enters New Phase**

• 

  10/3/2024

  **Emraclidine: A Potential Game-Changer for Schizophrenia Treatment**

• 

  10/3/2024

  **Profit from Quantum Opportunities**

• 

  10/2/2024

  **Consider This Undervalued Takeover Target**

• 10/2/2024

  **Avidity Biosciences: Compelling Oligonucleotide Program Worth Watching**

• 10/2/2024

  **FDA Approves Phase 1 Trials for AI-Discovered Cancer Treatment**

• 10/2/2024

  **Eli Lilly Invests $4.5B in New Research and Manufacturing Hub**

• 10/1/2024

  **Apellis Pharmaceuticals: Navigating CHMP Setback**